Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Lymphoid 1Dermatologic 1

Conditions

Uterine Cervical Dysplasia 2Squamous Intraepithelial Lesions 2Skin Neoplasms 1Sarcoma, Kaposi 1Lymphoproliferative Disorders 1HIV Infections 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone × Clear all
NCT00285207 2010-10-11

Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

Tigris Pharmaceuticals

Phase 2 Completed
147 enrolled 6 charts
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT00596258 2009-05-22

TG-003

Tigris Pharmaceuticals

Phase 2 Completed
11 enrolled
Gynecologic

Squamous Intraepithelial Lesions, Uterine Cervical Dysplasia

NCT00002153 2005-06-24

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

NIH AIDS Clinical Trials Information Service

Phase 1 Completed
25 enrolled
DermatologicLymphoidSarcoma

Acquired Immunodeficiency Syndrome, Lymphoproliferative Disorders, Sarcoma, Kaposi, Skin Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡